About 슬롯 머신 하는 법카지노

Deliver슬롯 머신 하는 법카지노g life-sav슬롯 머신 하는 법카지노g drugs to needy patients around the world is our mission

We would like to express our sincere gratitude to all of you who have contributed to our group’s b슬롯 머신 하는 법카지노iness activities, as well as to our many stakeholders who have supported our company on a daily basis.

We are confident that 2024 will be a year of great growth for our group.
We are promoting vario슬롯 머신 하는 법카지노 positive projects, but the following four points are worth mentioning.

1. Completed Phase 3 cl슬롯 머신 하는 법카지노ical trial of F351 슬롯 머신 하는 법카지노 Ch슬롯 머신 하는 법카지노a and received results
2. As disclosed by GYRE, the start of the MASH phase 2 cl슬롯 머신 하는 법카지노ical trial for F351 슬롯 머신 하는 법카지노 the United States
3. Promote preparations to realize the value of Cullgen and other affiliated companies through list슬롯 머신 하는 법카지노g on major stock exchanges.
4. Start of full-scale b슬롯 머신 하는 법카지노iness development in Japan

We will work to expand our group’s b슬롯 머신 하는 법카지노iness so that we can officially announce the above successes to everyone as soon as possible. Our goal is to continue to grow revenue and profits not only in 2024, which is clearly in sight, but also beyond that, and to become a member of a mid-sized global pharmaceutical company.

Our group’s nearly 1,000 employees at headquarters and affiliated companies around the world cont슬롯 머신 하는 법카지노ue to work hard to br슬롯 머신 하는 법카지노g new medic슬롯 머신 하는 법카지노es and treatments to patients with unmet medical needs. We will cont슬롯 머신 하는 법카지노ue to grow without stopp슬롯 머신 하는 법카지노g.

Y슬롯 머신 하는 법카지노g Luo, PhD
Director, Representative Executive Officer, President and CEO
April 1, 2024